Cipla USA Inc. Initiates Class II Recall for Phytonadione Injectable Emulsion Due to Stability Failure
Cipla USA Inc. has initiated a Class II recall for 4,438 cartons of Phytonadione Injectable Emulsion, USP 10mg/mL, distributed nationwide. This voluntary action stems from out-of-specification results for color index, indicating a critical stability failure. Procurement and regulatory teams must assess supply chain resilience for this essential Vitamin K product, manufactured by Cipla Ltd. India, to mitigate potential disruption.
FDA Class II Recall: Cipla USA Inc.'s Phytonadione Injectable Emulsion Fails Stability
Cipla USA Inc. has initiated a voluntary Class II recall, identified as D-0197-2026, for specific batches of its Phytonadione Injectable Emulsion, USP 10mg/mL. This critical action, initiated on October 31, 2025, and classified by the FDA on November 28, 2025, targets 4,438 10x1mL cartons distributed nationwide across the USA. The primary reason cited for this recall is a failure in stability specifications, specifically the observation of out-of-specification (OOS) results for the product's color index. This indicates a potential degradation of the active pharmaceutical ingredient or excipients, which can compromise efficacy and safety. For procurement directors and supply chain VPs, this event necessitates an immediate assessment of current inventory and pipeline for Phytonadione. Reliance on the affected batches (PH0072404A and PH0082404A, both with an expiration date of December 31, 2025) could lead to significant supply disruptions for a critical medication. Regulatory affairs heads must understand that a Class II recall signifies a situation where the use of or exposure to the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification still demands swift action to mitigate patient risk and ensure compliance.
Phytonadione's Critical Role: Market Impact of Supply Disruption
Phytonadione, commonly known as Vitamin K1, is a vital human prescription drug with significant therapeutic importance. It is primarily utilized to increase prothrombin activity and reverse the effects of anticoagulation, making it an essential warfarin reversal agent. Administered via intramuscular, intravenous, or subcutaneous routes, Phytonadione is indispensable in clinical settings for managing patients with coagulation disorders, vitamin K deficiency, or those experiencing excessive bleeding due to anticoagulant therapy. Its role as a rapid-acting antidote for anticoagulant overdose underscores its critical status in emergency medicine and chronic disease management. For business development executives, this recall highlights potential market vulnerabilities and opportunities. A disruption in the supply of a critical medication like Phytonadione can create immediate demand for alternative sources. Procurement teams must prioritize identifying and qualifying new suppliers to ensure continuity of care, as even a temporary shortage of a warfarin reversal agent can have severe patient safety implications. This incident emphasizes the need for a diversified supplier base for essential medicines to safeguard against unforeseen quality issues and maintain robust healthcare infrastructure.
Global Supply Chain Vulnerabilities: India Manufacturing and US Distribution
The recalled Phytonadione Injectable Emulsion was manufactured by Cipla Ltd. India at M/s Immacule Lifesciences PVT. Ltd. India, located in Pithampur, District Dhar. Cipla USA Inc., based in Warren, NJ 07059, is the entity for whom the product was manufactured and is responsible for initiating the recall across the USA. This manufacturing and distribution pathway underscores the intricate nature of global pharmaceutical supply chains, where a quality issue at an overseas facility can directly impact patient access to critical medicines in the United States. For procurement directors and supply chain VPs, this event serves as a stark reminder of the inherent risks associated with sourcing essential injectable drugs from international manufacturing sites. It necessitates a rigorous re-evaluation of supplier auditing and qualification processes, particularly for facilities in regions like India, to ensure consistent product quality and stability throughout the supply chain. The nationwide distribution pattern means that the impact of this recall is widespread, demanding a coordinated response to manage existing stock and secure reliable alternative supplies. This incident reinforces the strategic imperative of understanding and mitigating geographic and manufacturing-site specific risks within your pharmaceutical supply network.
Quality Control Imperatives: Addressing Out-of-Specification Results for Injectables
The observed out-of-specification (OOS) results for the color index of Phytonadione Injectable Emulsion are a significant quality concern. For parenteral products, color changes can be indicative of chemical degradation, the formation of impurities, or a loss of potency, all of which directly impact patient safety and therapeutic efficacy. Such stability failures highlight potential deficiencies in raw material quality, manufacturing processes, packaging integrity, or storage conditions. Adherence to robust stability testing protocols, as mandated by regulatory bodies, is crucial for ensuring product quality throughout its shelf life. For regulatory affairs heads, this incident underscores the paramount importance of stringent quality control and stability testing protocols. Ensuring that internal quality systems are robust enough to detect and prevent such deviations from reaching the market is non-negotiable. While not a sterility issue, the Class II classification still points to potential reversible adverse health consequences, reinforcing the need for proactive quality management. Furthermore, recent parallel events, such as the June 2026 FDA Class II recall of Essential Wellness Pharma's Progesterone Injection due to sterility assurance failures, signal a broader regulatory focus on injectable product quality and manufacturing compliance across the industry. This demands heightened vigilance and investment in quality infrastructure from all pharmaceutical stakeholders.
Remediation Pathways and Future Regulatory Scrutiny for Cipla USA Inc.
With the Class II recall (D-0197-2026) for Phytonadione Injectable Emulsion currently ongoing, Cipla USA Inc. and its manufacturing partner, Cipla Ltd. India, are now tasked with implementing a comprehensive remediation plan. This plan will involve a thorough investigation into the root cause of the color index OOS results, an assessment of the impact on other batches and products manufactured at the Pithampur, District Dhar facility, and potentially significant revisions to manufacturing processes, analytical methods, or stability protocols. The FDA will closely monitor these corrective and preventive actions (CAPAs) to ensure they effectively address the underlying quality system deficiencies. For procurement directors, monitoring Cipla's remediation progress is crucial. Delays or insufficient corrective actions could lead to prolonged supply disruptions or even further regulatory enforcement, impacting the long-term availability of Phytonadione from this supplier. Regulatory affairs teams should anticipate increased scrutiny from the FDA on future product submissions and facility inspections related to the involved manufacturing site. Business development executives should consider the potential for market shifts if Cipla's ability to reliably supply this critical product is compromised, creating opportunities for competitors with robust quality systems and diversified manufacturing capabilities.